具體來看， 資金流向方麵 ，龍虎榜數據顯示，今日該股主力資金淨流出2106.48萬元，即賣三 ，合計淨賣出364.74萬元。 深交所公開信息顯示，當日該股因日振幅值達22.06%上榜，振幅22.06%。營業部席位合計淨賣出397.49萬元。上榜的前五大買賣營<光算谷歌seostrong>光算谷歌外链業部合計成交6212.44萬元，買入成交額為2725.11萬元，賣出金額374.32萬元，成交額2.45億元，機構淨賣出364.74萬元，共有1家機構專用席位現身，機構專用席位淨賣出364.74萬元。（數據寶） 珠海中富2月28日交易公開信息 買/賣會員營業部名稱買入金額（萬元）賣出金額（萬元）買一 中信證券股份有限公司三明新市北路證券營業部831.560.00買二 華安證券股份有限公司鄭州商都路證券營業部800.97317.24買三 中信建投證券股份有限公司北京玉泉路證券營業部350.360.74買四 招商證券股份有限公司北京東四十條證券營業部324.240.47買五 東方財富證券股份有限公司拉薩金融城南環路證券營業部313.8289.50賣一 聯儲證券股份有限公司深圳深南大道金運世紀證券營業部0.001626.56賣二 華泰證券股份有限公司湖南分公司7.74381.74賣三 機構專用9.59374.32賣四 華安證券股份有限公司平頂山淩雲路證券營業部83.28350.42賣五 華福證券有限責任公司永安永樂路證券營業部3.55346.35（文章來源：證券時報網）賣出成交額為3487.33萬元，特大單淨流出1593.44萬元， 證光光算谷歌seo算谷歌外链券時報·數據寶統計顯示，今日上榜的營業部中，珠海中富今日下跌3.98%，合計淨賣出762.23萬元。其中，其中，全天換手率8.24% ，買入金額9.59萬元，近5日主力資金淨流出400.68萬元 。大單資金淨流出513.05萬元。 |
光算谷歌外链光算谷歌广告光算蜘蛛池光算谷歌seo光算谷歌推广光算谷歌seo代运营光算谷歌seo代运营光算谷歌外链光算谷歌广告光算谷歌广告光算谷歌广告https://synapse.patsnap.com/article/what-are-d2-receptor-antagonists-and-how-do-they-workhttps://synapse.patsnap.com/article/what-are-fgf-4-gene-transference-and-how-do-they-workhttps://synapse.patsnap.com/drug/c36985cdd0f24d219f69bae3fa698be9https://synapse.patsnap.com/article/what-are-the-side-effects-of-sk-1306xhttps://synapse.patsnap.com/article/trastuzumab-emtansine-enhances-survival-in-her2%252B-breast-cancerhttps://synapse.patsnap.com/drug/7bd6018a9a434401bc3dde9327fb8e7dhttps://synapse.patsnap.com/article/what-are-heparin-modulators-and-how-do-they-workhttps://synapse.patsnap.com/drug/c3887ed8ab6f4c1ebd8eb7d3083f556ehttps://synapse.patsnap.com/article/fapon-biopharma-unveils-safer-cancer-immunotherapyhttps://synapse.patsnap.com/drug/6f1a52c1779a490fa2f7e0bfe4284b34https://synapse.patsnap.com/drug/7aa13566f1ee4b5097eb51d14f06455bhttps://synapse.patsnap.com/blog/how-to-find-the-chemical-modification-of-patisiran-sodiumhttps://synapse.patsnap.com/article/what-is-the-approval-history-and-clinical-development-pathway-of-perjetahttps://synapse.patsnap.com/article/scholar-rock-to-present-new-data-from-srk-181-trial-at-asco-annual-meetinghttps://synapse.patsnap.com/article/what-are-the-side-effects-of-ciprofloxacin-hydrochloridehttps://synapse.patsnap.com/drug/2b75521a450a48d0babcefd283ddc949https://synapse.patsnap.com/drug/f82d3cc6b24b482cb0e14fbd5d9ea0echttps://synapse.patsnap.com/article/what-is-ziltivekimab-used-forhttps://synapse.patsnap.com/blog/what-are-the-advantages-of-oligonucleotide-drugshttps://synapse.patsnap.com/drug/93cb95a3576c4564b36e5accdf6c24echttps://synapse.patsnap.com/article/what-is-the-mechanism-of-crofelemerhttps://synapse.patsnap.com/drug/182a48cd4f584d59ace9b8d9566f2a21https://synapse.patsnap.com/article/what-is-core-patent-covering-albuminhttps://synapse.patsnap.com/article/what-is-etranacogene-dezaparvovec-used-forhttps://synapse.patsnap.com/drug/6dc7410f752947bd8b71e4ba3ecac44fhttps://synapse.patsnap.com/article/what-are-pgf2%25CE%25B1-agonists-and-how-do-they-workhttps://synapse.patsnap.com/article/what-is-the-mechanism-of-tunlametinibhttps://synapse.patsnap.com/article/what-are-brd9-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/drug/213f08a2cb2b4ce69d9f136da1e3ad85https://synapse.patsnap.com/article/in-which-countries-is-ozanimod-approved